# Combined entity to have revenue of $12.4 billion; enters biosimilars big league.

*biotech · news · 2026-04-27 · Business Standard*

## Key points

- Sun Pharma will acquire Organon for $11.75 billion in one of India's largest outbound deals.
- The combined entity will have $12.4 billion revenue, entering the top 25 global pharmaceutical firms.
- Sun Pharma becomes a top-three global player in women’s health and seventh in biosimilars.
- The acquisition establishes an innovative medicines portfolio accounting for 27% of combined revenues.

**Companies:** Sun Pharmaceutical Industries, Merck & Co, Organon & Co
**Countries:** India, United States, China, Brazil

[Read the full story on Business Standard](https://www.business-standard.com/companies/news/sun-pharma-to-buy-organon-for-11-75-bn-enter-top-25-global-pharma-list-126042700382_1.html)

---

Canonical: https://newsio.io/n/16c07a93-7701-42e1-b898-5ba395046a95/combined-entity-to-have-revenue-of-12-4-billion-enters-biosimilars-big-league-th
Summarized by Newsio from Business Standard. https://newsio.io/how-it-works